Heat shock protein 90

Current Opinion in Oncology

Volumn 15, Issue 6, 2003, Pages 419-424

  Neckers, Len ^a,b   Ivy, S Percy ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b National Cancer Institute ^*  (United States)

Author keywords

Geldanamycin; Heat shock protein 90; Molecular chaperones; Molecular targeting

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUTANT PROTEIN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LEUKEMIA; LYMPHOMA; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VOMITING;

CELL SURVIVAL; CLINICAL TRIALS, PHASE I; GENES, ERBB-2; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0742287264     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200311000-00003     Document Type: Review

References (49)

1. Jacobsohn DA: Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs 2002, 11:1271-1280.
2. Garber K: Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 2001, 93:1517-1519.
3. Pearl LH, Prodromou C: Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem 2001, 59:157-186.
4. Blagosklonny MV: Hsp-90-associated oncoproteins: multiple targets of gel-danamycin and its analogs. Leukemia 2002, 16:455-462.
5. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002, 8:S55-S61.
6. Picard D: Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci 2002, 59:1640-1648.
7. Workman P: Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. Cancer Detect Prev 2002, 26:405-410.
8. Isaacs JS, Xu W, Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217.
9. Vanaja DK, Mitchell SH, Toft DO, et al.: Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002, 7:55-64. A comprehensive analysis of the role of Hsp90 in androgen receptor ligand binding and stability.
10. Georget V, Terouanne B, Nicolas J-C, et al.: Mechanism of antiandrogen action: key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry (Mosc) 2002, 41:11824-11831. A careful cell biology-based analysis of Hsp90 mediation of androgen receptor signaling.
11. Solit D, Zheng F, Drobnjak M, et al. 17-Allylamino-17- demthoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002:986-993. An exciting preclinical study demonstrating the in vivo effectiveness of 17-AAG in both a hormone-dependent and hormone-independent xenograft model of prostate cancer.
12. Basso AD, Solit DB, Chiosis G, et al.: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002, 277:39858-39866. A comprehensive biochemical analysis of the role of Hsp90 in the stability and function of Akt.
13. Basso AD, Solit DB, Munster PN, et al.: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21:1159-1166. An important study that highlights the supersensitivity of Akt to Hsp90 inhibition in the context of Her2 overexpression.
14. Munster PN, Marchion DC, Basso AD, Rosen N: Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 2002, 62:3132-3137. A report of preclinical data documenting the ability of 17-AAG to enhance the toxicity of Taxol in a Her-2-overexpressing breast cancer xenograft model.
15. Smith V, Hobbs S, Court W, et al.: ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res 2002, 22:1993-1999.
16. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2002, 2:38-47.
17. Maxwell PH, Wiesener MS, Chang G-W, et al.: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
18. Seizinger BR, Rouleau GA, Ozelius LJ, et al.: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268-269.
19. Gradin K, McGuire J, Wenger RH, et al.: Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 1996, 16:5221-5231.
20. Hur E, Kim HH, Choi SM, et al.: Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 2002, 62:975-982. A description of the effects of an alternative Hsp90 inhibitor on the stability and function of HIF-1α.
21. Isaacs JS, Jung YJ, Mimnaugh EG, et al.: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002, 277:29936-29944. The first report showing that Hsp90-dependent stabilization of HIF-1α is independent of VHL, thus identifying a second, chaperone-dependent HIF-1α degradative pathway.
22. Mabjeesh NJ, Post DE, Willard MT, et al.: Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteasome pathway in prostate cancer cells. Cancer Res 2002, 62:2478-2482. An article that documents the sensitivity of HIF-1α to Hsp90 inhibition in normoxic prostate cancer cells.
23. Zagzag D, Nomura M, Friedlander DR, et al.: Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1 alpha) in glioma cell invasion. J Cell Physiol 2003, 196:394-402. A study that correlates Hsp90 inhibition in glioma cells with inhibition of motility.
24. Dias S, Shmelkov SV, Lam G, et al.: VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002, 99:2532-2540. A comprehensive report demonstrating the key role of Hsp90 in mediating VEGF induced survival of both endothelial and cancer cells.
25. Maulik G, Kijima T, Ma PC, et al.: Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002, 8:620-627. A key study demonstrating that Hsp90 inhibitors can downregulate Met kinase function in small-cell lung cancer cells.
26. Pennacchietti S, Michieli P, Galluzzo M, et al.: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361. An important article that documents hypoxia-induced activation of the Met pathway.
27. Tacchini L, Dansi P, Matteucci E, et al.: Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 2001, 22:1363-1371.
28. Bottaro DP, Liotta LA: Out of air is not out of action. Nature 2003, 423:593-595.
29. Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996, 271:22796-22801.
30. Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al.: Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 1996, 93:14536-14541.
31. An WG, Schulte TW, Neckers LM: The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000, 11:355-360.
32. French BA, van Leeuwen F, Riley NE, et al.: Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin. Exp Mol Pathol 2001, 71:241-246.
33. Waelter S, Boeddrich A, Lurz R, et al.: Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001, 12:1393-1407.
34. Aghajanian C, Soignet S, Dizon DS, et al.: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002, 8:2505-2511.
35. L'Allemain G: [Update on ... the proteasome inhibitor PS341]. Bull Cancer 2002, 89:29-30.
36. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002, 99:14374-14379. A study showing that simultaneous addition of an Hsp90 inhibitor enhances the toxicity of a proteasome inhibitor in myeloma cells.
37. Fujimoto J, Shiota M, Iwahara T, et al.: Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 1996, 93:4181-4186.
38. Bonvini P, Gastaldi T, Falini B, et al.: Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin. Cancer Res 2002, 62:1559-1566. The first report to identify the lymphoma associated chimeric kinase NPM-ALK as an Hsp90 client sensitive to 17-AAG.
39. Naoe T, Kiyoe H, Yamamoto Y, et al.: FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother Pharmacol 2001, 48:S27-S30.
40. Minami Y, Kiyoi H, Yamamoto Y, et al.: Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002, 16:1535-1540. A study demonstrating the Hsp90 dependence of mutated FLT3 kinase, and the enhanced sensitivity of leukemia cells harboring this mutation to Hsp90 inhibition.
41. Shiotsu Y, Neckers LM, Wortman I, et al.: Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000, 96:2284-2291.
42. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
43. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
44. Shah NP, Nicoll JM, Nagar B, et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125. A demonstration that BCR-ABL kinase domain mutations that confer resistance to imatinib may be preexisting in patients with untreated chronic myeloid leukemia, and selected as a direct result of treatment with imatinib.
45. Gorre ME, Ellwood-Yen K, Chiosis G, et al.: BCR-ABL point mutants isolated from patients with STI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100:3041-3044. A careful study that documents the continued Hsp90 dependence of imatinib-resistant BCR-ABL protein, and thus its continued sensitivity to 17-AAG.
46. Nimmanapalli R, O'Bryan E, Huang M, et al.: Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2002, 62:5761-5769. A study that corroborates the findings reported in the previous reference, further strengthening the case for treatment of imatinib-resistant CML with 17-AAG.
47. Munster PN, Tong W, Schwartz L, et al.: Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2001b, 20:A326.
48. Banerji U, O'Donnell A, Scurr M, et al.: A pharmacokinetically (Pk)-pharmacodynamically (Pd) driven phase I trial of the Hsp90 molecular chaperone inhibitor 17-allyamino 17-demethoxygeldanamycin (17AAG). Proc 93rd Annu Meet Am Assoc Cancer Res 2002, 43:A1352.
49. Agnew EB, Wilson RH, Morrison G, et al.: Clinical pharmacokinetics of 17-(allylamino)-17-demethoxygeldanamycin and the active metabolite 17-(amino)-17-demethoxygeldanamycin given as a one-hour infusion daily for 5 days. Proc 93rd Annu Meet Am Assoc Cancer Res 2002;43:A1349.